Literature DB >> 30560331

Use of Hepatitis C-Positive Liver Grafts in Hepatitis C-Negative Recipients.

Akshay Shetty1, Adam Buch2, Sammy Saab3,4,5.   

Abstract

As the demand for liver transplantation continues to rise, the scarcity of liver donor grafts has led to the use of extended criteria grafts for liver transplantation in select group of patients. Hepatitis C-seropositive liver grafts have been used primarily in hepatitis C-positive recipients, with studies showing non-inferior outcomes when compared to hepatitis C-negative grafts. Studies suggest that hepatitis C serology status of the donor liver does not influence the patient or graft outcomes in the recipient. These results advocate for offering hepatitis C-positive grafts to all patients awaiting liver transplantation regardless of their hepatitis C status. However, some concerns persist regarding the ethics of potentially introducing a new infection into a patient that could progress to chronic liver disease following liver transplantation. The recent approval of direct-acting antiviral therapy offers a solution to this dilemma, as it has changed the landscape of hepatitis C management by making it a curable disease. In this review, we shall discuss the current evidence regarding the use of hepatitis C-seropositive donor grafts in hepatitis C-positive and hepatitis C-negative patients.

Entities:  

Keywords:  DAA, direct-acting antiviral; Donor grafts; Hepatitis C liver transplantation; Hepatitis C-positive donor grafts; Liver transplantation

Mesh:

Substances:

Year:  2018        PMID: 30560331     DOI: 10.1007/s10620-018-5404-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  60 in total

1.  Utilization of hepatitis C virus RNA-positive donor liver for transplant to hepatitis C virus RNA-negative recipient.

Authors:  Behnam Saberi; James P Hamilton; Christine M Durand; Zhiping Li; Benjamin Philosophe; Andrew M Cameron; Mark S Sulkowski; Ahmet Gurakar
Journal:  Liver Transpl       Date:  2018-01       Impact factor: 5.799

Review 2.  Nucleic acid testing (NAT) of organ donors: is the 'best' test the right test? A consensus conference report.

Authors:  A Humar; M Morris; E Blumberg; R Freeman; J Preiksaitis; B Kiberd; E Schweitzer; S Ganz; A Caliendo; J P Orlowski; B Wilson; C Kotton; M Michaels; S Kleinman; S Geier; B Murphy; M Green; M Levi; G Knoll; Dorry L Segev; S Brubaker; R Hasz; D J Lebovitz; D Mulligan; K O'Connor; T Pruett; M Mozes; I Lee; F Delmonico; S Fischer
Journal:  Am J Transplant       Date:  2010-01-29       Impact factor: 8.086

3.  OPTN/SRTR 2013 Annual Data Report: liver.

Authors:  W R Kim; J R Lake; J M Smith; M A Skeans; D P Schladt; E B Edwards; A M Harper; J L Wainright; J J Snyder; A K Israni; B L Kasiske
Journal:  Am J Transplant       Date:  2015-01       Impact factor: 8.086

4.  Use of hepatitis C-positive grafts in hepatitis C-negative liver transplant recipients is cost effective.

Authors:  Sammy Saab; Ani Kardashian; Satvir Saggi; Gina Choi; Vatche Agopian; Myron J Tong
Journal:  Clin Transplant       Date:  2018-09-15       Impact factor: 2.863

5.  Recurrent and new hepatitis C virus infection after liver transplantation.

Authors:  J E Everhart; Y Wei; H Eng; M R Charlton; D H Persing; R H Wiesner; J J Germer; J R Lake; R K Zetterman; J H Hoofnagle
Journal:  Hepatology       Date:  1999-04       Impact factor: 17.425

6.  Nucleic acid testing to detect HBV infection in blood donors.

Authors:  Susan L Stramer; Ulrike Wend; Daniel Candotti; Gregory A Foster; F Blaine Hollinger; Roger Y Dodd; Jean-Pierre Allain; Wolfram Gerlich
Journal:  N Engl J Med       Date:  2011-01-20       Impact factor: 91.245

7.  Impact of donor and recipient hepatitis C status in lung transplantation.

Authors:  Brian R Englum; Asvin M Ganapathi; Paul J Speicher; Brian C Gulack; Laurie D Snyder; R Duane Davis; Matthew G Hartwig
Journal:  J Heart Lung Transplant       Date:  2015-10-09       Impact factor: 10.247

8.  Utilization, outcomes, and retransplantation of liver allografts from donation after cardiac death: implications for further expansion of the deceased-donor pool.

Authors:  Fred W Selck; Eric B Grossman; Lloyd E Ratner; John F Renz
Journal:  Ann Surg       Date:  2008-10       Impact factor: 12.969

9.  Twelve-Month Outcomes After Transplant of Hepatitis C-Infected Kidneys Into Uninfected Recipients: A Single-Group Trial.

Authors:  Peter P Reese; Peter L Abt; Emily A Blumberg; Vivianna M Van Deerlin; Roy D Bloom; Vishnu S Potluri; Matthew Levine; Paige Porrett; Deirdre Sawinski; Susanna M Nazarian; Ali Naji; Richard Hasz; Lawrence Suplee; Jennifer Trofe-Clark; Anna Sicilia; Maureen McCauley; Caren Gentile; Jennifer Smith; Bijan A Niknam; Melissa Bleicher; K Rajender Reddy; David S Goldberg
Journal:  Ann Intern Med       Date:  2018-08-07       Impact factor: 25.391

10.  Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.

Authors:  Christine M Durand; Mary G Bowring; Diane M Brown; Michael A Chattergoon; Guido Massaccesi; Nichole Bair; Russell Wesson; Ashraf Reyad; Fizza F Naqvi; Darin Ostrander; Jeremy Sugarman; Dorry L Segev; Mark Sulkowski; Niraj M Desai
Journal:  Ann Intern Med       Date:  2018-03-06       Impact factor: 51.598

View more
  3 in total

Review 1.  When Theory Becomes Reality: Navigating the Ethics of Transplanting Hepatitis C Virus-Positive Livers Into Negative Recipients.

Authors:  Thomas Couri; Andrew Aronsohn
Journal:  Clin Liver Dis (Hoboken)       Date:  2019-11-06

2.  Donor Characteristics and Regional Differences in the Utilization of HCV-Positive Donors in Liver Transplantation.

Authors:  Ben L Da; Ghideon Ezaz; Tatyana Kushner; James Crismale; Gaurav Kakked; Ahmet Gurakar; Douglas Dieterich; Thomas D Schiano; Behnam Saberi
Journal:  JAMA Netw Open       Date:  2020-12-01

Review 3.  Recent advances in liver transplantation with HCV seropositive donors.

Authors:  Soumya Murag; Brittany B Dennis; Donghee Kim; Aijaz Ahmed; George Cholankeril
Journal:  F1000Res       Date:  2019-12-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.